News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lightlake Therapeutics Inc. to Conduct Phase II Testing of New Bulimia Nervosa Treatment at King's College London


10/5/2011 10:17:50 AM

LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company using its expertise of opioid antagonists to develop modern addiction treatments, announced today that it will conduct Phase II trials at King’s College London on an opioid antagonist-based nasal spray treatment for Bulimia Nervosa.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES